BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Targacept, Inc. 

200 East First Street
Suite 300
Winston-Salem  North Carolina  27101-4165  U.S.A.
Phone: 336-480-2100 Fax: 336-480-2107


View Clinical Trials from BioPharm Insight

Targacept, Inc. is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with AstraZeneca and is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies.

Targacept’s news releases are available on its website at

 Key Statistics

Ownership: Public

Web Site: Targacept, Inc.
Employees: 120
Symbol: TRGT

 Company News
Targacept, Inc. (TRGT) To Present At The 13th Annual Needham Healthcare Conference 4/2/2014 7:47:03 AM    More...
Targacept, Inc. (TRGT) Reports Fourth Quarter And 2013 Financial Results 2/13/2014 8:04:36 AM    More...
Targacept, Inc. (TRGT) Completes Recruitment In Phase 2b Overactive Bladder Trial Of TC-5214 2/10/2014 9:46:40 AM    More...
Targacept, Inc. (TRGT) Appoints John P. Richard As Chairman Of The Board Of Directors 1/8/2014 8:51:54 AM    More...
Targacept, Inc. (TRGT) Announces Negative Top-Line Results From Phase 2b Clinical Trial Of TC-5619 In Schizophrenia 12/17/2013 9:52:54 AM    More...
Targacept, Inc. (TRGT) Announces Negative Top-Line Results From Phase 2b Clinical Trial Of TC-5619 In Schizophrenia 12/17/2013 7:29:07 AM    More...
Targacept, Inc. (TRGT) Announces Presentations At Upcoming Conferences 11/14/2013 9:37:12 AM    More...
Targacept, Inc. (TRGT) Reports Third Quarter 2013 Financial Results 11/5/2013 7:12:02 AM    More...
Targacept, Inc. (TRGT) to Report Third Quarter 2013 Financial Results on November 5, 2013 10/29/2013 6:49:01 AM    More...
Targacept, Inc. (TRGT) Reports Second Quarter 2013 Financial Results 8/6/2013 7:40:33 AM    More...